Adaptimmune(ADAP)
搜索文档
Adaptimmune(ADAP) - 2019 Q4 - Earnings Call Transcript
2020-02-28 04:58
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2019 Earnings Conference Call February 27, 2020 8:00 AM ET Company Participants Juli Miller - Director of Investor Relations Adrian Rawcliffe - Chief Executive Officer Helen Tayton-Martin - Chief Business Officer Elliot Norry - Chief Medical Officer Conference Call Participants Tony Butler - Roth Capital Marc Frahm - Cowen and Company Kelsey Goodwin - Guggenheim Securities James Shannon - Citi Jonathan Chang - SVB Leerink Operator Ladies and gentlemen, thank you ...
Adaptimmune(ADAP) - 2019 Q4 - Annual Report
2020-02-28 00:50
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (St ...
Adaptimmune(ADAP) - 2019 Q3 - Earnings Call Transcript
2019-11-10 21:50
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Q3 2019 Earnings Conference Call November 6, 2019 8:00 AM ET Company Participants Juli Miller - Director, IR Adrian Rawcliffe - CEO, Principal Accounting Officer & Director Elliot Norry - Acting Chief Medical Officer John Lunger - Chief Patient Supply Officer Michael Garone - Interim CFO Conference Call Participants Mohit Bansal - Citigroup Marc Frahm - Cowen and Company Tony Butler - Roth Capital Partners Nicholas Abbott - Wells Fargo Securities Michael Schmidt - ...
Adaptimmune(ADAP) - 2019 Q3 - Quarterly Report
2019-11-07 00:55
Table of Contents ADAP The Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Ap ...
Adaptimmune(ADAP) - 2019 Q2 - Earnings Call Transcript
2019-08-04 05:42
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2019 Results Conference Call August 1, 2019 8:00 AM ET Company Participants Juli Miller - IR James Noble - CEO Adrian Rawcliffe - Incoming CEO Rafael Amado - President, R&D Conference Call Participants Waleed Abdel-Naby - SunTrust Robinson Humphrey Kelsey Goodwin - Guggenheim Securities Marc Frahm - Cowen Keith Tapper - Citi Jonathan Chang - SVB Leerink Jim Birchenough - Wells Fargo Tony Butler - Roth Capital Partners Operator Good morning, and welcome to the Se ...
Adaptimmune(ADAP) - 2019 Q2 - Quarterly Report
2019-08-01 23:59
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other jurisdiction of i ...
Adaptimmune(ADAP) - 2019 Q1 - Quarterly Report
2019-05-07 02:57
Table of Contents ADAP The Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applic ...